teaser
Roche and Biogen Idec’s cancer drug Rituxan has been found to extend the lives of follicular lymphoma patients, according to a late-stage study.
The disease is a common, incurable but slow-developing form of non-Hodgkin’s lymphoma (NHL) and accounts for about one in four of all cases.
↓Article continues below this sponsored advert↓
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
↑Advertisement↑
The study was stopped early after Rituxan, known as MabThera outside the US, met its target of extending the time patients live with their disease under control during a pre-planned interim analysis. Rituxan is co-marketed by Genentech.
Copyright Press Association 2009
